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We retrospectively evaluated the accumulation of ﬂuorodeoxy glucose (FDG) in pulmonary malignan-
cies without local recurrence during 2-year follow-up on positron emission tomography (PET)/com-
puted tomography (CT) after radiofrequency ablation (RFA).  Thirty tumors in 25 patients were stud-
ied (10 non-small cell lung cancers; 20 pulmonary metastatic tumors).  PET/CT was performed before 
RFA,  3 months after RFA,  and 6 months after RFA.  We assessed the FDG accumulation with the 
maximum standardized uptake value (SUVmax) compared with the diameters of the lesions.  The 
SUVmax had a decreasing tendency in the ﬁrst 6 months and,  at 6 months post-ablation,  FDG accu-
mulation was less aﬀected by inﬂammatory changes than at 3 months post-RFA.  The diameter of the 
ablated lesion exceeded that of the initial tumor at 3 months post-RFA and shrank to pre-ablation 
dimensions by 6 months post-RFA.  SUVmax was more reliable than the size measurements by CT in 
the ﬁrst 6 months after RFA,  and PET/CT at 6 months post-RFA may be more appropriate for the 
assessment of FDG accumulation than that at 3 months post-RFA.
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adiofrequency ablation (RFA) has gained increas-
ing acceptance as an intervention technique for 
the local control of non-small cell lung cancers 
(NSCLC) and pulmonary metastatic tumors [1-3],  
and the evaluation of ablated tumors has become more 
important in the follow-up period.  However,  the 
morphologic modality of computed tomography (CT) 
and magnetic resonance imaging (MRI) has not been 
suﬃcient for surveillance of post-RFA lung tumors 
because of peritumoral inﬂammation and bleeding,  
especially in the early period after RFA [4-6].  
Fluorine-18-ﬂuorodeoxyglucose positron emission 
tomography (F-18 FDG-PET) is now a standard 
nuclear imaging modality for staging and for follow-up 
after radiotherapy and chemotherapy in patients with 
pulmonary malignancy [7-11].  Several investigators 
have shown that F-18 FDG PET/CT is helpful in the 
evaluation of the therapeutic response after RFA for 
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lung tumors and have discussed the timing of PET/CT 
after pulmonary RFA in retrospective studies [5,  12,  
13].  In one preliminary study,  F-18 FDG-PET at 2 
months after RFA predicted regrowth [5].  However,  
another report has determined that the diagnostic 
accuracy of PET/CT in the ﬁrst 3 months after RFA 
was not suﬃcient,  suggesting that the appropriate 
follow-up initiation time point was at least 3 months 
after RFA [12].  We evaluated F-18 FDG accumula-
tion at pre-RFA,  3 months post-RFA,  and 6 months 
post-RFA with semiquantitative analyses of the maxi-
mum standardized uptake value (SUVmax) and the 
retention index (RI) of SUVmax (RI-SUVmax) and 
compared these evaluations with evaluation of the 
lesion size.  The aims of this retrospective study were 
to investigate whether size measurement by CT or 
SUVmax measurement by F-18 FDG PET/CT is 
more reliable in the early (ﬁrst 6 months) follow-up 
after RFA and to determine which time point is more 
appropriate,  3 months or 6 months post-RFA.
Materials and Methods
　 Patient population. This is a retrospective 
review of the prospective electronic database of the 
radiology department of a single center (Okayama 
University Hospital).  Patients who underwent LeVeen 
needle pulmonary RFA between January 2007 and 
June 2008 (196 tumors in 112 patients; 36 NSCLC,  
160 pulmonary metastatic tumors).  Only patients who 
underwent both CT with intravenous administration of 
contrast medium and F-18 FDG PET/CT studies at 
pre-RFA and 3 months and 6 months post-RFA were 
included.  Patients were excluded if they had local 
recurrence or had received adjuvant chemotherapy 
during the 2 years following RFA.  There were 30 
tumors that met these conditions,  10 NSCLC and 20 
pulmonary metastatic tumors,  in 16 men and 9 women 
aged 64.89±13.79 years (mean ± SD),  range,  51 to 
94 years.
　 This retrospective study was approved by the ethi-
cal committee of Okayama University Graduate School 
of Medicine,  which waived informed consent from the 
patients.
　 Approval from the institutional review board and 
informed consent from the patients had previously 
been obtained to perform RFA.
　 RFA technique. The RFA procedure was 
always performed percutaneously under CT ﬂuoros-
copy (Asteion; Toshiba,  Tokyo,  Japan).  The elec-
trodes used included a multitined expandable electrode 
with a 2-cm (n＝10),  3-cm (n＝14),  3.5-cm (n＝4),  
and 4-cm (n＝2) diameter array (LeVeen; Boston 
Scientiﬁc,  Natick,  MA,  USA).  The electrode was 
introduced into the tumor and was connected to an RF 
generator (RF2000 or 3000 generator,  Boston 
Scientiﬁc,  for multitined expandable electrodes).  The 
numbers of ablations performed per lesion were 4.20
±1.55 for NSCLC and 3.95±1.15 for metastatic 
tumors; the diﬀerence between them was not statisti-
cally signiﬁcant (p＝0.5916).  The ablation durations 
were 30.61±10.93 min for NSCLC and 24.48±13.29 
min for metastatic tumors; again,  no signiﬁcant dif-
ference was identiﬁed between them (p＝0.2184).
　 Post-RFA monitoring. Post-RFA monitoring 
was performed by chest CT with intravenous contrast 
(Iopamidol,  Iopamiron300; Bayer HealthCare) and 
PET/CT examinations on the same day,  on both the 
ﬁrst (median 95 days) and second monitoring visits 
(median 187 days).  When evaluated for the presence 
of local tumor recurrence after RFA by 2-year clini-
cal follow-up including contrast-enhanced CT,  all 
patients included in the present study were without 
local recurrence.  The eﬀectiveness of RFA was 
assessed on the basis of the CT images as follows:  
when the entire ablation zone was not contrast-
enhanced or when the ablation zone had contrast 
enhancement,  but it was peripheral,  concentric,  sym-
metric,  and uniform,  with smooth inner margins,  the 
tumor was considered to be completely treated,  
whereas an irregular,  scattered,  nodular,  or eccen-
tric enhancement in the ablation zone or circumferen-
tial tumor enlargement with contrast enhancement was 
considered to indicate local tumor progression.  These 
radiological assessments were carried out by the con-
sensus of 2 radiologists unaware of the clinical results.
　 F-18 FDG PET/CT. PET image acquisition 
started 90 min after injection of FDG with the patient 
in a relaxed supine position using an integrated PET/
CT scanner (Biograph LS/Sensation16,  Siemens,  
Munchen,  Germany) at Okayama Diagnostic Imaging 
Center.  Patients had been instructed to fast for at 
least 5h,  after which blood glucose levels were deter-
mined to ensure a level of ＜140mg/dL.  Patients then 
received an intravenous injection of 3.7MBq/kg (1.0
×10-4Ci/kg) body weight FDG.  The patients were 
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asked to remain resting on a reclining chair to mini-
mize FDG consumption by the muscles just before 
scans.  First,  a total-body low-dose CT scan for calcu-
lation of attenuation correction was performed,  using 
a standardized protocol involving 140kV,  12 to 
14mAs,  a tube-rotation time of 0.5 s per rotation,  a 
pitch of 0.8,  a section thickness of 3mm,  and scan 
ﬁeld from head up to the mid-thigh level (consisting of 
7-8 bed positions with 2.4 min per table position).  
The PET images were reconstructed with an ordered-
subset expectation maximization (OSEM) iterative 
reconstruction algorithm.  Integrated,  coregistered 
PET/CT images were obtained using a workstation 
(PET Viewer,  AZE),  which enabled image fusion and 
analysis.
　 Image data analysis. Two nuclear physicians 
unaware of the chest CT results interpreted all F-18 
FDG PET/CT ﬁndings by consensus.  For semiquan-
titative analyses of FDG uptakes,  the SUV was 
adopted.  SUVs were calculated using lean body mass 
as follows: SUV＝radioactivity in regions of interest 
(ROI) (Bq/mL)×lean body mass (kg)/injected radio-
activity (Bq).  Circular ROIs were drawn to encom-
pass the entire tumor using the PET/CT image.  To 
minimize partial-volume eﬀects,  the SUVmax values 
within ROIs were used.  The SUVmax was obtained 
before RFA (SUV1),  3 months after RFA (SUV2),  
and 6 months after RFA (SUV3) for all pulmonary 
tumors,  NSCLC and pulmonary metastatic tumors.  
Furthermore,  we calculated RI-SUVmax from the 
SUVmax (3 or 6 months post-RFA) according to the 
following formula: RI-SUVmax (ｵ)＝(SUVmax [3 or 
6 months post-RFA]－baseline SUVmax [pre-RFA])
×100/baseline SUVmax (pre-RFA).
　 On chest CT images,  the long-axis diameters of 26 
target lesions (lesionsｧ10mm) were calculated.  At 3 
and 6 months after RFA,  the response to ablation was 
evaluated based on Response Evaluation Criteria in 
Solid Tumors (RECIST) version 1.1 criteria [14].  
According to RECIST,  “complete response” (CR) is 
deﬁned as tumor disappearance or scarring,  “partial 
response” (PR) as a decrease of more than 30ｵ in 
maximum tumor diameter,  “progressive disease” (PD) 
as more than a 20ｵ increase in maximum tumor diam-
eter and 5-mm absolute increase,  and “stable disease” 
(SD) as a decrease of no more than 30ｵ or an 
increase of no more than 20ｵ in tumor diameter.
　 Statistical analysis. Wilcoxon signed-rank U 
test or Studentʼs t test was used to determine the 
significance of differences in SUVmax and 
RI-SUVmax among all of the study groups.  Studentʼs 
t test or the Mann-Whitney U test was used to deter-
mine the signiﬁcance of diﬀerences between CT-deﬁned 
PD and SD groups in SUVmax at 3 and 6 months 
after RFA and the percentage changes in CT mea-
surements at 3 and 6 months after RFA relative to the 
size before RFA.  All statistical analysis was per-
formed using the Statview 5.0 (SAS institute Inc.,  
Berkeley,  CA,  USA).  Probability values ＜0.05 were 
taken to indicate signiﬁcant diﬀerences.
Results
　 Characteristics of Patients and Pulmonary 
tumors. The study included 9 patients (5 men and 
4 women,  mean age 71.44±7.72 years) with 10 soli-
tary NSCLCs and 16 patients (8 men and 8 women,  
mean age 67.06±9.82 years) with 20 pulmonary meta-
static tumors.  Histopathologically,  there were 8 
adenocarcinomas and 2 squamous cell carcinomas in the 
patients with NSCLC.  The pulmonary metastatic 
tumors included 13 from colorectal cancer,  2 from 
hepatocellular carcinoma,  2 from renal cell carci-
noma,  2 from esophageal cancer,  and 1 from oropha-
ryngeal cancer (Table 1).  Eleven nodules were 
assessed as PD and 15 nodules were assessed as SD 
at 3 months post-RFA on RECIST.  Six nodules were 
assessed as PD and 20 nodules were assessed as SD 
at 6 months post-RFA on RECIST.
　 Maximum standardized uptake values and 
retention index of SUVmax. Table 2 shows 
SUVmax values at each time point for all study 
groups.  The mean and median SUVmax values were 
4.6 and 3.98 (range 1.18 to 11.2) for SUV1,  4.29 and 
3.9 (range 1.1 to 10.6) for SUV2,  and 2.95 and 1.9 
(range 0.83 to 8.09) for SUV3 in all pulmonary 
tumors (Fig.  1).  The mean and median SUVmax val-
ues were 4.4 and 4.32 (range 1.18 to 10.3) for SUV1,  
4.34 and 3.8 (range 1.39 to 8.03) for SUV2,  and 2.87 
and 2.5 (range 0.9 to 6.32) for SUV3 in NSCLC.  The 
mean and median SUVmax values were 4.70 and 3.65 
(range 1.25 to 11.2) for SUV1,  4.21 and 3.9 (range 
1.1 to 10.6) for SUV2,  and 2.99 and 1.9 (range 0.83 
to 8.09) for SUV3 in the pulmonary metastatic 
tumors.
　 The SUV1 was signiﬁcantly higher than SUV3 in 
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all pulmonary tumors (p＝0.0157) and in the pulmo-
nary metastatic tumors (p＝0.032).  The SUV2 was 
signiﬁcantly higher than SUV3 in all pulmonary 
tumors (p＝0.021) and in the pulmonary metastatic 
tumors (p＝0.022).  No signiﬁcant diﬀerence was 
identiﬁed between SUV1 and SUV2 in all pulmonary 
tumors (p＝0.5885) and the pulmonary metastatic 
tumors (p＝0.6211).  No signiﬁcant diﬀerence was 
identiﬁed between SUV1 and SUV2 (p＝0.9587),  
between SUV1 and SUV3 (p＝0.1327),  or between 
SUV2 and SUV3 (p＝0.1109) in NSCLC.
　 Median RI-SUVmax were －3.4ｵ (range －81.91 
to 272.03ｵ) for those at 3 months post-RFA,  and 
－32.9ｵ (range －87.61 to 160.99ｵ) for those at 6 
months post-RFA.  The RI-SUVmax was signiﬁcantly 
lower at 6 months post-RFA than at 3 months post-
RFA (p＝0.0329).
　The SUVmax values at 3 months post-RFA were 
4.16±2.28 in the PD group and 4.18±2.85 in the 
SD group (Table 3).  No signiﬁcant diﬀerence was 
identiﬁed in the SUVmax between the PD and SD 
groups (p＝0.983).  The SUVmax values at 6 months 
post-RFA were 3.13±2.16 in the PD group and 2.80
±2.12 in the SD group (Table 3).  No signiﬁcant dif-
ference was identiﬁed in the SUVmax between the PD 
and SD groups (p＝0.7396).
　 Lesion size over time after pulmonary RFA.
The long-axis diameters of all pulmonary tumors 
108 Acta Med.  Okayama　Vol.  67,  No.  2Alafate et al.
Table 1　 Characteristics of solitary non-small cell lung cancer (NSCLC) and pulmonary metastatic tumor
NSCLC
10 nodules in 9 patients (5 men and 4 women; age,  71.44±7.72 years; range 54-78 years)
No of lesions Size (mm)
Adenocarcinoma  8 15.4
Squamous cell carcinoma  2  7.5
Clinical Stage
　　　　　IA (T1N0M0)  7 14.0
　　　　　IB (T2N0M0)  3 11.6
Size of nodules: 20.90±11.87mm (mean ± SD),  range 6.0-42.0mm
Pulmonary metastatic tumors
20 nodules in 16 patients (8 men and 8 women; age,  67.06±9.82 years; range 51-94 years)
No of lesions Size (mm)
Colorectal cancer 13  9.0
Hepatocellular carcinoma  2 11.5
Renal cell carcinoma  2 17.0
Esophageal cancer  2  9.5
Oropharyngeal cancer  1 20.0
Size of nodules: 11.15±4.44mm (mean ± SD),  range 5.0-30.0mm
SD,  standard deviation.
Table 2　 Results of SUVmax and tumor size at each time point in each groups
pre-RFA 3 mo after RFA 6 mo after RFA
All pulmonary tumors (n＝30) 4.60±2.65＊ 4.29±2.54† 2.95±2.07
Non-small cell lung cancers (n＝10) 4.40±2.56　 4.34±2.20　 2.87±1.68
Metastatic pulmonary tumors (n＝20) 4.70±2.75＊ 4.21±2.78† 2.99±2.28
Tumors size of all pulmonary tumors (mm) 11.5±1.62‡ 19.0±2.70　 15.5±1.73
SUV,  standardized uptake value.
The data represent mean ± standard devision.
＊p＜0.05 versus 6 months after RFA: †p＜0.05 versus 6 months after RFA; ‡p＜0.05 versus 3 months after RFA
ranged from 5 to 42mm with a mean of 11.4 and a 
median of 11.5mm at pre-RFA.  The long-axis lesion 
diameters were 20.9±11.87mm in NSCLC and 11.15
±4.44mm in metastatic tumors at pre-RFA.  A sig-
niﬁcant diﬀerence was identiﬁed in the size of pulmo-
nary tumors at pre-RFA between NSCLC and meta-
static tumors (p＝0.0449).  The long-axis diameter of 
the pulmonary lesions ranged from 7 to 73mm with a 
mean of 24.13mm and a median of 19mm at 3 months 
post-RFA,  and from 5 to 52mm with a mean of 
17.96mm and a median of 15.5mm at 6 months post-
RFA (Fig.  2).  A signiﬁcant diﬀerence was found 
between pre-RFA and 3 months post-RFA in the long-
axis diameter of pulmonary lesions (p＝0.001).  No 
signiﬁcant diﬀerence in long-axis lesion diameter was 
identiﬁed between pre-RFA and 6 months post-RFA 
(p＝0.1376),  or between 3 month- and 6 months post-
RFA (p＝0.0593).  The median values of the percent-
age changes in CT measurements at 3 months post-
RFA were 133.0ｵ (range 21.4 to 275.0ｵ) in the PD 
group and 13.0ｵ (range 0 to 57.0ｵ) in the SD group 
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Fig. 1　 Change of SUVmax over time after radiofrequency abla-
tion.  The graph shows signiﬁcant diﬀerences for the median 
SUVmax between pre-RFA and 6 months after RFA (p＝0.0157),  
and between 3 month- and 6 month-after RFA (p＝0.021) in all 
tumors.  However,  no signiﬁcant diﬀerences were identiﬁed for the 















Fig. 2　 Change of mean lesion size over time after radiofre-
quency ablation.  The graph demonstrates that the size of pulmo-
nary tumor at 3 month-after ablation was signiﬁcantly larger than 
pre-RFA (p＝0.001).  There were no signiﬁcant diﬀerences in size 
between pre-RFA and 6 month-after RFA,  and the change between 
3 month- and 6 month-after RFA was not statistically signiﬁcant.
Table 3　 Summary of data by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
PD group SD group
No. of tumors
　　　　3 mo after RFA 11 15
　　　　6 mo after RFA  6 20
SUVmax (mean ± SD)
　　　　3 mo after RFA 4.16±2.28 4.18±2.85
　　　　6 mo after RFA 3.13±2.16 2.80±2.12
Percent reduction in size (median ± SEM)
　　　　3 mo after RFA 133.0±24.22%＊ 13.0±3.94%＊
　　　　6 mo after RFA 138.2±16.20%＊ 0.0±3.188%＊
SUV,  standardized uptake value; PD,  progressive disease; SD,  stable disease.
＊p＜0.05 versus SUVmax in CT-deﬁned PD and SD groups (Mann-Whiteny U test).
(Table 3).  The median values of the percentage 
changes in CT measurements varied signiﬁcantly 
between the PD and SD groups (p＜0.0001).  The 
median values of the percentage changes in CT mea-
surements at 6 months after RFA were 138.2ｵ 
(range 55.6 to 157.1ｵ) in the PD group and 0.0ｵ 
(range －28.6 to 17.7ｵ) in the SD group (Table 3).  
The median values of the percentage changes in CT 
measurements diﬀered signiﬁcantly between the PD 
and SD groups (p＝0.0002).  Fig.  3 shows the CT 
images of a pulmonary metastatic tumor from rectal 
carcinoma during the 2-year follow-up after RFA.
Discussion
　 The present study assessed the accumulation of 
F-18 FDG in pulmonary lesions with semiquantitative 
analyses on PET/CT at 3 and 6 months after patients 
underwent RFA with a LeVeen needle.  We found a 
decreasing tendency of FDG accumulation at the site 
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Fig. 3　 CT images after pulmonary RFA in patients with metastatic tumor from rectal carcinoma.  A,  Pre-RFA CT of 62-year-old male 
with pulmonary metastatic tumor in the right upper lobe; B,  C,  D The follow-up CT examination showed the dimension of tumor had 
enlarged at 3 months after RFA(B).  The dimension of tumor had gradually shrunk during the ﬁrst 24 months after RFA.  At 6 month- and 24 
month-after ablation,  there was the vessels enhancement at the peripheral of the ablated lesion; however CT showed no irregular 
enhancement within the ablated lesions (C,  D).  There was no tumor enlargement with contrast enhancement at each time points.
of pulmonary lesions in ﬁrst 6 months.  FDG accumu-
lation was less aﬀected by inﬂammatory changes at 6 
months than at 3 months after RFA.  We also analyzed 
the size change of the ablated lesion on CT and found 
that the diameter of the ablated lesion exceeded that 
of the initial tumor at the ﬁrst 3 months and then 
shrank to pre-ablation dimensions,  also indicating that 
PET/CT study at 6 months post-RFA may be more 
appropriate for the assessment of FDG accumulation 
in pulmonary lesions than PET/CT study at 3 months 
post-RFA.
　 In the present study,  we demonstrated that there 
is a decreasing tendency of FDG accumulation in pul-
monary tumors within the ﬁrst 6 months after RFA 
and that median SUVmax at pre-RFA was signiﬁcantly 
higher than that at 6 months post-RFA in pulmonary 
tumors without tumor regrowth.  There was no sig-
niﬁcant diﬀerence between the median SUVmax at 
pre-RFA and that at 3 months post-RFA.  Moreover,  
we demonstrated that the RI-SUVmax at 6 months 
post-ablation was signiﬁcantly lower than at 3 months 
post-ablation.  Higaki et al. reported that the diagnos-
tic accuracy of PET/CT within 3 months after RFA 
was not suﬃcient,  owing to the marked inﬂammatory 
change following ablation [12].  These ﬁndings suggest 
that 6 months after LeVeen needle pulmonary RFA is 
a more appropriate follow-up initiation time point 
compared with 3 months post-ablation.
　 Okuma et al. reported that tumor regrowth,  as 
demonstrated by CT at 6 or more months after 
LeVeen needle pulmonary RFA,  could be predicted 
earlier with SUVmean and RI-SUVmean on FDG-
PET at 2 months after ablation compared with CT 
evaluation [5].  The discrepancy of these ﬁndings with 
our results may be attributed to diﬀerences in study 
design.  There were diﬀerences in choice between 
SUVmax and SUVmean for semiquantitative analysis 
of FDG uptakes.  In the studies for FDG uptake with 
SUV analyses,  SUVmax is generally used rather than 
SUVmean because it is suggested that SUVmax is less 
dependent on the placement and drawing of the ROIs 
[15].  Moreover,  SUVmean is proposed to be less 
variable because its reproducibility is worse than that 
of SUVmax and SUVmean is subject to operator bias 
[16].
　 In the present study,  the SUV1 and the SUV2 
were signiﬁcantly higher than SUV3 in metastatic 
tumors.  However,  no signiﬁcant diﬀerence was identi-
ﬁed among time points in NSCLC.  The mean size of 
the pulmonary lesion at pre-RFA was signiﬁcantly 
larger in NSCLC than in metastatic tumors.  No sig-
niﬁcant diﬀerences were identiﬁed between NSCLC 
and metastatic tumors in the numbers of ablations and 
ablation time; however,  the mean number of ablations 
was larger and the ablation duration longer in NSCLC 
than in metastatic tumors.  We hypothesized that,  in 
the present study,  RFA procedures for the NSCLC 
would need more ablations and longer ablation times 
due to the larger size of NSCLC than metastatic 
tumors.  These factors would prolong the inﬂamma-
tory changes following ablation and increase the FDG 
uptake in pulmonary lesions of NSCLC.  The number 
of lesions in NSCLC was smaller,  and that might have 
had the potential to erase the diﬀerences in SUVmax 
among the diﬀerent time points.
　 Another ﬁnding of this study was that the size of 
pulmonary tumors at 3 months after ablation was sig-
niﬁcantly larger than that at pre-RFA,  and that the 
mean and median sizes of pulmonary tumors at 6 
months post-ablation were smaller than those at 3 
months but still larger than those before RFA.  
Moreover,  we did not identify any signiﬁcant diﬀer-
ence between the CT-deﬁned PD and SD groups in the 
SUVmax at either 3 and 6 months post-RFA.  Okuma 
et al. reported that LeVeen needle-ablated lesions 
appeared larger on CT performed immediately after 
ablation because of the surrounding parenchymal 
edema,  inﬂammation,  and hemorrhage caused by RFA 
thermal damage [5].  Steinke et al. demonstrated that 
lesions ablated with multitined expandable electrodes 
are typically expected to be bigger at 1 week after 
RFA than at baseline,  and then to slowly decrease in 
size.  At 3 months after RFA,  the lesions may still be 
larger than at baseline,  and at 6 months after RFA,  
they may be the same size or smaller than before 
RFA [17].  These ﬁndings suggest that size compari-
son of pulmonary tumors after RFA with multitined 
expandable electrodes is not useful for prediction of 
local recurrences in the early 6 months,  and that the 
SUVmax values have the potential to more precisely 
reﬂect the condition in the ablated region compared 
with size comparisons,  even at 3 months post-RFA.
　 Our study has several limitations.  First,  the 
sample sizes were relatively small for the primary 
lung cancers and the pulmonary metastatic tumors.  
Second,  our study design was retrospective.  Third,  
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there was no histopathological conﬁrmation after 
RFA.  Finally,  the present study consists of pulmo-
nary lesions without local recurrence,  as conﬁrmed by 
2-year clinical follow-up.  Therefore,  there is no 
comparison with the FDG uptake by recurrent lesions 
after RFA.  A larger number of patients in a prospec-
tive study using histological examinations after RFA,  
with comparison of FDG uptake between the pulmo-
nary tumors with and without recurrence,  would be 
useful for further investigation of the appropriate 
timing of F-18 PET/CT in post-RFA pulmonary 
tumors.
　 Despite these limitations,  our results suggest the 
possibility of providing a more appropriate evaluation 
of FDG accumulation in pulmonary lesions after RFA 
by using F-18 FDG PET/CT at 6 months rather than 
3 months post-RFA.  Size comparison of the pulmo-
nary lesions did not prove useful for evaluation of local 
recurrences within 6 months of RFA.
　 In conclusion,  we analyzed semiquantitatively the 
accumulation in lung tumors on PET/CT before RFA,  
at 3 months after RFA,  and at 6 months after RFA 
compared with the size ofthe pulmonary lesions at the 
same time point.  The size comparison of pulmonary 
tumorsafter RFA was not useful for prediction of local 
recurrences in the ﬁrst 6 months afterablation,  and 
the accumulation at 3 months after RFA was greater 
than at 6 months. PET/CT at 6 months could provide 
a more appropriate evaluation of the FDG accumula-
tion in pulmonary lesions than that at 3 months.
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